Ionis Pharmaceuticals, Inc. and Xencor, Inc.: A Comprehensive Revenue Analysis

Biotech Giants: Ionis vs. Xencor Revenue Battle

__timestamp	Ionis Pharmaceuticals, Inc.	Xencor, Inc.
Wednesday, January 1, 2014	214161000	9520000
Thursday, January 1, 2015	283703000	27762000
Friday, January 1, 2016	346620000	87520000
Sunday, January 1, 2017	507666000	35711000
Monday, January 1, 2018	599674000	40603000
Tuesday, January 1, 2019	1123000000	156700000
Wednesday, January 1, 2020	729000000	122694000
Friday, January 1, 2021	810000000	275111000
Saturday, January 1, 2022	587000000	164579000
Sunday, January 1, 2023	787647000	168338000

Data in motion

A Decade of Revenue Growth: Ionis Pharmaceuticals vs. Xencor

In the ever-evolving biotech industry, Ionis Pharmaceuticals and Xencor have carved out significant niches. From 2014 to 2023, Ionis Pharmaceuticals demonstrated a robust revenue trajectory, peaking in 2019 with a remarkable 1.12 billion USD, a 424% increase from 2014. Despite a dip in 2022, Ionis rebounded in 2023 with a 34% increase from the previous year. Xencor, while smaller in scale, showcased impressive growth, particularly in 2021, where revenue surged by 1,800% compared to 2014. This growth underscores the dynamic nature of the biotech sector, where innovation and strategic partnerships drive financial success. As these companies continue to innovate, their financial narratives offer valuable insights into the broader trends shaping the biotech landscape.

Published by

U.S. Securities and Exchange Commission

Source link

sec.gov

Date published

17 Jan 2025